Upstream Bio, Inc. UPB
2.88 USD -0.33 (-10.16%)
Nov 12, 2026, 1:54 PM EST
2.82 Day range 3.13
2.68 52-week range 33.68
- YTD
- -89.41%
- 1 year
- -87.88%
News
benzinga.com HC Wainwright & Co. Maintains Buy on Upstream Bio, Lowers Price Target to $18 HC Wainwright & Co. analyst Matthew Caufield maintains Upstream Bio (NASDAQ:UPB) with a Buy and lowers the price target from $36 to $18.
defenseworld.net Upstream Bio, Inc. (NASDAQ:UPB) Stock Has Average Price Target of $29.67 According to Analysts Upstream Bio, Inc. (NASDAQ: UPB - Get Free Report) has been given a consensus rating of "Hold" by the seven analysts that are currently covering the firm, MarketBeat reports. One equities research…
zacks.com Upstream Bio, Inc. (UPB) Reports Q3 Loss, Lags Revenue Estimates Upstream Bio, Inc. (UPB) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to a loss of $0.63 per share a year ago.
benzinga.com Upstream Bio Q3 EPS $(0.75) Misses $(0.72) Estimate, Sales $395.000K Miss $480.143K Estimate Upstream Bio (NASDAQ:UPB) reported quarterly losses of $(0.75) per share which missed the analyst consensus estimate of $(0.72) by 4.17 percent. This is a 19.05 percent decrease over losses of…
globenewswire.com Upstream Bio Reports Third Quarter 2026 Financial Results and Highlights Continued Progress – Company plans to initiate Phase 3 trials in both severe asthma and CRSwNP in the first quarter of 2027 –- benzinga.com HC Wainwright & Co. Reiterates Buy on Upstream Bio, Maintains $36 Price Target HC Wainwright & Co. analyst Matthew Caufield reiterates Upstream Bio (NASDAQ:UPB) with a Buy and maintains $36 price target.
benzinga.com JP Morgan Maintains Neutral on Upstream Bio, Raises Price Target to $9 JP Morgan analyst Tessa Romero maintains Upstream Bio (NASDAQ:UPB) with a Neutral and raises the price target from $8 to $9.
benzinga.com Truist Securities Maintains Buy on Upstream Bio, Lowers Price Target to $25 Truist Securities analyst Danielle Brill maintains Upstream Bio (NASDAQ:UPB) with a Buy and lowers the price target from $43 to $25.
benzinga.com Upstream Bio Q2 EPS $(0.73) Beats $(0.76) Estimate, Sales $773.000K Beat $430.714K Estimate Upstream Bio (NASDAQ:UPB) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.76) by 3.95 percent. This is a 1.35 percent increase over losses of $(0.74)…
benzinga.com Reported Sunday, Upstream Bio Presents Phase 2 VIBRANT Data Showing 79% Of Verekitug-Treated CRSwNP Patients Achieved Clinically Meaningful Nasal Polyp Score Improvements Versus 24% On Placebo – Verekitug, administered once every three months, led to clinically meaningful improvements in nasal polyp score (NPS) in approximately 80% of participants –– Majority of verekitug-treated…- benzinga.com JP Morgan Downgrades Upstream Bio to Neutral, Lowers Price Target to $8 JP Morgan analyst Tessa Romero downgrades Upstream Bio (NASDAQ:UPB) from Overweight to Neutral and lowers the price target from $35 to $8.
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session - benzinga.com Upstream Bio to Present New Verekitug Data at EAACI 2026, Phase 2 Nasal Polyps Analysis Gets EAACI Oral Presentation Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that additional data…
- benzinga.com HC Wainwright & Co. Initiates Coverage On Upstream Bio with Buy Rating, Announces Price Target of $36 HC Wainwright & Co. analyst Matthew Caufield initiates coverage on Upstream Bio (NASDAQ:UPB) with a Buy rating and announces Price Target of $36.
benzinga.com Upstream Bio Presents New Data From Phase 2 VIBRANT Trial Evaluating Verekitug In Participants With Chronic Rhinosinusitis With Nasal Polyps At ATS 2026 International Conference – Verekitug led to statistically significant and clinically meaningful improvement in asthma symptom control as measured by the Asthma Control Questionnaire-6 (ACQ-6) in participants with CRSwNP and…
benzinga.com Mizuho Maintains Outperform on Upstream Bio, Lowers Price Target to $50 Mizuho analyst Joseph Catanzaro maintains Upstream Bio (NASDAQ:UPB) with a Outperform and lowers the price target from $51 to $50.- benzinga.com Upstream Bio Q1 EPS $(0.75) Beats $(0.77) Estimate, Sales $1.034M Beat $442.000K Estimate Upstream Bio (NASDAQ:UPB) reported quarterly losses of $(0.75) per share which beat the analyst consensus estimate of $(0.77) by 2.6 percent. This is a 47.06 percent decrease over losses of $(0.51)…
- benzinga.com Upstream Bio Announces Presentation Of New Data From Phase 2 VIBRANT Trial At American Thoracic Society Meeting On May 18 The presentations feature new data from the Phase 2 VIBRANT trial evaluating verekitug, the only known antagonist to the thymic stromal lymphopoietin (TSLP) receptor currently in clinical…
benzinga.com From Lungs To Nasal Polyps: Sanofi Finds Success With 2-in-1 Inflammation Blocker Sanofi reports positive Phase 2 data for lunsekimig in asthma and nasal polyps, while atopic dermatitis study misses main goal.- benzinga.com Evercore ISI Group Downgrades Upstream Bio to In-Line, Lowers Price Target to $15 Evercore ISI Group analyst Cory Kasimov downgrades Upstream Bio (NASDAQ:UPB) from Outperform to In-Line and lowers the price target from $40 to $15.
benzinga.com Zenas Biopharma, Daqo New Energy And Other Big Stocks Moving Lower In Friday's Pre-Market Session U.S. stock futures down, Zenas Biopharma shares fall 9.5% in pre-market trading due to pricing of public offerings. Other stocks also lower.
benzinga.com Upstream Bio Lead Drug Pivotal Trial Plan Follows Strong Phase 2 Data Upstream Bio outlines Phase 3 plans for verekitug as asthma and CRSwNP data support dosing strategy; shares rise on update.- benzinga.com Upstream Bio Plans To Initiate Dosing In Phase 3 Trials In Both Severe Asthma And CRSwNP In Q1 2027 – Company to pursue Phase 3 development strategy designed to deliver best-in-class efficacy with a high-dose quarterly regimen in broad patient populations in both severe asthma and CRSwNP –– Company…
benzinga.com Peering Into Upstream Bio Inc's Recent Short Interest 
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session 
benzinga.com Upstream Bio's Selloff May Be 'Overdone,' But Analyst Highlights Asthma Drug's Competitive Edge Concerns Upstream Bio stock fell after mixed asthma drug data, but analysts say the selloff may be overdone despite competition concerns.
benzinga.com Crude Oil Gains Over 1%; US Economy Adds 130,000 Jobs In January - benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com Upstream Bio Shows Asthma Drug Cuts Attacks By 56%, Stock Reacts Upstream Bio shares rise after Phase 2 data show its asthma drug cut attacks by up to 56% and improved lung function. The company plans late-stage trials.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session - benzinga.com Upstream Bio Releases Topline Data From Phase 2 VALIANT Trial Of Verekitug For Severe Asthma, Meeting The Primary Endpoint Of Annualized Asthma Exacerbation Rate Verekitug provided statistically significant and clinically meaningful reductions in annualized asthma exacerbation rate (AAER) with 100 mg q12 and 400 mg q24 week dosing.Verekitug also delivered…
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session 
benzinga.com Canopy Growth, Nvidia And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session 
benzinga.com Alerus Financial Posts Better-Than-Expected Earnings, Joins Celcuity, SES AI, Abercrombie & Fitch And Other Big Stocks Moving Higher On Monday - benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com Amtech Systems, Tesla And Other Big Stocks Moving Lower In Thursday's Pre-Market Session 
benzinga.com Why ReShape Lifesciences Shares Are Trading Higher By Over 82%; Here Are 20 Stocks Moving Premarket